Arcutis Biotherapeutics Inc (ARQT)
NASDAQ:ARQT
Want to see ARQT full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.04Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call described strong underlying commercial momentum and meaningful clinical and pipeline progress: 65% YoY revenue growth, share gains, positive operating cash flow, pediatric submissions, and initiation of ARQ-234 Phase I. These positives are tempered by a seasonality- and weather-driven Q1 demand dip (-6% QoQ for ZORYVE), continued material gross-to-net pressure (in the 50s), near-term SG&A/R&D increases, and limited Part D coverage today. Management emphasized that recent investments (sales force expansion, PCP/pediatric build, DTC) will drive demand in H2 2026 and a larger inflection in 2027, and they maintained full-year guidance of $480M–$495M.Company Guidance
Strong Revenue Growth
Net product revenues of $105.4M in Q1 2026, up 65% year-over-year, driven primarily by increased patient demand and improved gross-to-net performance.
Sustained Prescription Momentum
ZORYVE reached approximately 21,000 prescriptions per week (rolling 4-week average, IQVIA) with sustained Rx growth; quarter-to-date through April 24, Q2 scripts are ~13% higher versus Q1 in the same time period.
Market Share Gains
ZORYVE's share of total branded non-steroidal topical prescriptions increased to 48% in Q1 (a +3 percentage point increase from end of 2025); ZORYVE accounted for 48% of new-to-brand Rx among branded non-steroidal topicals in Q1.
Positive Gross-to-Net Trend
Gross-to-net remained in the 50s and improved versus Q1 2025 due to improved formulary positioning; company expects to transition from higher-50s early in the year to low-50s by year-end 2026.
Maintained Full-Year Revenue Guidance
Company maintained 2026 revenue guidance of $480M–$495M despite Q1 seasonality; management expects growth to resume as seasonality and weather impacts normalize.
Positive Operating Cash Flow Achieved
Arcutis reported positive cash flow in the quarter with $2.2M net cash provided by operating activities and cash & marketable securities of $224.3M as of March 31, 2026; management expects to maintain positive quarterly cash flow through 2026.
Commercial Rollouts and Organizational Build
Completed dermatology sales force expansion (new reps in field as of the call) and initiated build-out of a targeted primary care and pediatric team (hired Katie Swoss as Head); expected field impact beginning Q3 with PCP/peds influence in late 2026–2027.
Pediatric/Infant Label Expansion Progress
Submitted supplemental NDA in April 2026 for ZORYVE cream 0.05% for atopic dermatitis in infants aged 3–24 months; submission occurred three months after topline INTEGUMENT infant results.
Compelling INTEGUMENT Infant Data
INTEGUMENT infant Phase II: over one-third of infants achieved VIGA-AD success (IGA 0/1 with ≥2-grade improvement) at week 4; ~50% achieved clear/almost clear at week 4; 58.3% achieved EASI-75 at week 4; rapid itch relief observed (nearly 50% had 25% itch improvement within 10 minutes; ~66% within 4 hours).
Regulatory & Pediatric Psoriasis Activity
Completed enrollment in MUSE trial for ZORYVE foam 0.3% in children 2–11 with scalp/body psoriasis; supplemental NDA for ZORYVE cream 0.3% down to age 2 is under FDA review with a PDUFA date of June 29, 2026.
Pipeline Advancement – ARQ-234 Initiated
Initiated Phase I trial of ARQ-234 (CD200R agonist) with single-ascending dose (SAD) in healthy volunteers underway and planned multiple-ascending dose (MAD) and proof-of-concept cohorts in moderate-to-severe atopic dermatitis; positions company to build beyond ZORYVE.
Multiple Proof-of-Concept Programs Enrolling
Phase II POC enrollment nearing completion in vitiligo (on track for a Q4 2026 readout) and enrolling in hidradenitis suppurativa (HS) with a similar readout expected in Q1 2027.
ARQT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARQT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $24.17 | $20.66 | -14.52% |
Feb 25, 2026 | $27.01 | $28.57 | +5.78% |
Oct 28, 2025 | $19.64 | $24.95 | +27.04% |
Aug 06, 2025 | $15.36 | $14.12 | -8.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcutis Biotherapeutics Inc (ARQT) report earnings?
Arcutis Biotherapeutics Inc (ARQT) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Arcutis Biotherapeutics Inc (ARQT) earnings time?
Arcutis Biotherapeutics Inc (ARQT) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARQT EPS forecast?
ARQT EPS forecast for the fiscal quarter 2026 (Q2) is 0.04.